Impact of diabetes mellitus severity, treatment regimen and glycaemic control on atrial fibrillation prevalence in the Polish population aged ≥ 65.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 10 2023
12 10 2023
Historique:
received:
06
03
2023
accepted:
30
09
2023
medline:
1
11
2023
pubmed:
13
10
2023
entrez:
12
10
2023
Statut:
epublish
Résumé
Diabetes mellitus (DM) is a well-known risk factor for atrial fibrillation (AF), but the mechanism(s) by which DM affects AF prevalence remains unclear. This study aims to evaluate the impact of diabetes mellitus severity (expressed as its known duration), antihyperglycemic treatment regimen and glycaemic control on AF prevalence. From the representative sample of 3014 participants (mean age 77.5, 49.1% female) from the cross-sectional NOMED-AF study, 881 participants (mean age 77.6 ± 0.25, 46.4% female) with concomitant DM were involved in the analysis. AF was screened using a telemonitoring vest for a mean of 21.9 ± 9.1 days. The mean DM duration was 12 ± 0.35 years, but no significant impact of DM timespan on AF prevalence was observed. No differences in the treatment pattern (oral medication vs insulin vs both oral + insulin) among the study population with and without AF were shown (p = 0.106). Metabolic control reflected by HbA1c levels showed no significant association with AF and silent AF prevalence (p = 0.635; p = 0.094). On multivariate analyses, age (Odds Ratio (OR) 1.35, 95%CI: 1.18-1.53, p < 0.001), p = 0.042), body mass index (BMI; OR 1.043, 95%CI: 1.01-1.08, p = 0.027) and LDL < 100 mg/dl (OR 0.64, 95%CI: 0.42-0.97, p = 0.037) were independent risk factors for AF prevalence, while age (OR 1.45, 95%CI: 1.20-1.75, p < 0.001), LDL < 100 mg/dl (OR 0.43, 95%CI 0.23-0.82, p = 0.011), use of statins (OR 0.51, 95%CI: 0.28-0.94, p = 0.031) and HbA1c ≤ 6.5 (OR 0.46, 95%CI: 0.25-0.85, p = 0.013) were associated with silent AF prevalence. Diabetes duration, diabetic treatment pattern or metabolic control per se did not significantly impact the prevalence of AF, including silent AF detected by prospective continuous monitoring. Independent predictors of AF were age, BMI and low LDL levels, with statins and HbA1c ≤ 6.5 being additional independent predictors for silent AF.Trial registration: NCT03243474.
Identifiants
pubmed: 37828071
doi: 10.1038/s41598-023-43939-5
pii: 10.1038/s41598-023-43939-5
pmc: PMC10570325
doi:
Substances chimiques
Glycated Hemoglobin
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Insulins
0
Banques de données
ClinicalTrials.gov
['NCT03243474']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17252Informations de copyright
© 2023. Springer Nature Limited.
Références
Pol Arch Intern Med. 2023 Aug 30;133(7-8):
pubmed: 36861462
J Gen Intern Med. 2010 Aug;25(8):853-8
pubmed: 20405332
Eur Heart J. 2020 Jan 7;41(2):255-323
pubmed: 31497854
Kardiol Pol. 2018;76(10):1482-1485
pubmed: 30211437
Circulation. 2001 Mar 27;103(12):1638-43
pubmed: 11273990
Nat Rev Cardiol. 2017 Nov;14(11):627-628
pubmed: 28960189
Ann Med. 2016;48(3):119-27
pubmed: 26939743
BMJ. 2000 Aug 12;321(7258):412-9
pubmed: 10938049
J Am Coll Cardiol. 2012 Oct 9;60(15):1421-8
pubmed: 22981550
Int Heart J. 2009 Sep;50(5):627-41
pubmed: 19809211
Diabetologia. 2011 Oct;54(10):2544-51
pubmed: 21674176
Diabetologia. 2006 Aug;49(8):1761-9
pubmed: 16736131
N Engl J Med. 2008 Feb 7;358(6):580-91
pubmed: 18256393
J Am Coll Cardiol. 2016 Jan 26;67(3):239-47
pubmed: 26796386
N Engl J Med. 2011 Mar 3;364(9):818-28
pubmed: 21366473
Cardiovasc Diabetol. 2021 Jun 24;20(1):128
pubmed: 34167520
Am J Cardiol. 2019 Dec 15;124(12):1881-1888
pubmed: 31668346
Diabetes Obes Metab. 2019 Feb;21(2):210-217
pubmed: 30144274
Am J Cardiol. 2011 Jul 1;108(1):56-62
pubmed: 21529739
Am J Cardiol. 2014 Oct 15;114(8):1217-22
pubmed: 25159234
Int J Cardiol. 2012 Apr 19;156(2):156-9
pubmed: 21093939
Int J Cardiol. 2005 Dec 7;105(3):315-8
pubmed: 16274775
Lancet. 1998 Sep 12;352(9131):837-53
pubmed: 9742976
J Am Coll Cardiol. 2017 Sep 12;70(11):1325-1335
pubmed: 28882229
Thromb Haemost. 2022 Jan;122(1):20-47
pubmed: 34773920
Arch Cardiovasc Dis. 2015 Apr;108(4):269-76
pubmed: 25858534
Diabetes Care. 2004 Aug;27(8):2049-51
pubmed: 15277439
Diabetes Res Clin Pract. 2018 Apr;138:271-281
pubmed: 29496507
JAMA. 2004 Jan 21;291(3):335-42
pubmed: 14734596
N Engl J Med. 2008 Jun 12;358(24):2545-59
pubmed: 18539917
Cardiovasc Diabetol. 2015 Jan 15;14:5
pubmed: 25589001
Am J Cardiol. 2007 Jun 18;99(12A):34i-43i
pubmed: 17599423
Thromb Haemost. 2022 Mar;122(3):406-414
pubmed: 34020488
Circulation. 2011 Apr 12;123(14):1501-8
pubmed: 21444879
Eur Heart J. 2021 Feb 1;42(5):373-498
pubmed: 32860505
Thromb Haemost. 2021 Mar;121(3):270-278
pubmed: 32838473
N Engl J Med. 2015 Jun 4;372(23):2197-206
pubmed: 26039600
Cardiovasc Diabetol. 2018 Jun 8;17(1):83
pubmed: 29884191
Diabetes Res Clin Pract. 2015 Sep;109(3):476-84
pubmed: 26220013
Circulation. 2004 Mar 30;109(12):1497-502
pubmed: 15006999
Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28
pubmed: 30559228
JAMA. 2013 Nov 20;310(19):2050-60
pubmed: 24240932
Am Heart J. 2010 May;159(5):850-6
pubmed: 20435195